...
首页> 外文期刊>Journal of Chemical Technology & Biotechnology >Scalable culture of human induced pluripotent cells on microcarriers under xeno-free conditions using single-use vertical-wheel (TM) bioreactors
【24h】

Scalable culture of human induced pluripotent cells on microcarriers under xeno-free conditions using single-use vertical-wheel (TM) bioreactors

机译:使用单用垂直轮(TM)生物反应器在无异载体下的人诱导多能细胞对微载体的可扩展培养物

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND Human induced pluripotent stem cells (hiPSC) are expected to become powerful tools for disease modelling, for the discovery and testing of new drugs and, ultimately, for regenerative therapies. The success of these applications depends on the development of scalable bioprocesses capable of generating large numbers of hiPSC and derivatives. RESULTS CONCLUSION In this work, the novel vertical-wheel single-use bioreactors were used for the first time for the expansion of hiPSC under xeno-free conditions. Cultures were performed on microcarriers in two different scales of vessels (100 and 500 mL with 80 and 300 mL working volumes, respectively), leading to maximum cell densities up to 1.21 +/- 0.02 x 10(6) cells mL(-1) and volumetric productivities of 2.01 +/- 0.04 x 10(5) cells mL(-1) day(-1). The pluripotency as well as a normal karyotype were maintained after cell expansion. Consistency of the processes was confirmed with a different hiPSC line, which is an important aspect for a personalized medicine approach. The results here described demonstrate the feasibility of scalable production of hiPSC in a microcarrier-based system using vertical-wheel bioreactors. The protocols developed in this study provide a Good Manufacturing Practices (GMP)-compliant system for hiPSC manufacturing which may be an important step towards the successful implementation of hiPSC-based products. (c) 2018 Society of Chemical Industry
机译:背景技术人诱导的多能干细胞(HIPSC)预计将成为疾病建模的强大工具,用于发现和测试新药,最终用于再生疗法。这些应用的成功取决于能够产生大量HIPSC和衍生物的可扩展生物过程的开发。结果结束在这项工作中,新颖的垂直轮单用生物反应器首次用于肝脏免条件下的HIPSC扩张。在两个不同的容器(分别为800mL的500ml的血管中的微载体上对培养物进行,导致最大细胞密度高达1.21 +/- 0.02×10(6)个细胞m1(-1)和体积的生产率为2.01 +/- 0.04×10(5)个细胞m1(-1)天(-1)。在细胞膨胀后保持多能性以及正常的核型。用不同的HIPSC线路确认了该过程的一致性,这是个性化医学方法的一个重要方面。这里的结果描述了使用垂直轮生物反应器的基于微载体的系统中HIPSC可扩展生产的可行性。本研究中开发的协议提供了一种良好的制造实践(GMP) - 用于HIPSC制造的替换系统,这可能是迈向河口基础产品的成功实施的重要一步。 (c)2018化学工业协会

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号